Profile of brivaracetam and its potential in the treatment of epilepsy

Figures & data

Table 1 Six randomized, placebo-controlled trials of adjunctive BRV in patients with uncontrolled seizures

Trial	ITT population (seizure type)	Brivaracetam range	Responder rates ≥50% for PBO and BRV
French et al^Citation27	BRV 154	5–50 mg/day	16.7% for PBO
	PBO 54 (partial)		32.0% for BRV 5 mg/day*
			44.2% for BRV 20 mg/day*
			55.8% for BRV 50 mg/day*
Van Paesschen et al^Citation28	BRV 105	50–150 mg/day	17.3% for PBO
	PBO 52 (partial)		35.8% for BRV 50 mg/day*
			30.8% for BRV 150 mg/day
Ryvlin et al^Citation29	BRV 298	20–100 mg/day	20.0% for PBO
	PBO 100 (partial)		27.3% for BRV 20 mg/day
			27.3% for BRV 50 mg/day
			36.0% for BRV 100 mg/day*
Biton et al^Citation30	BRV 298	5–50 mg/day	16.7% for PBO
	PBO 98 (partial)		21.9% for BRV 5 mg/day
			23.2% for BRV 20 mg/day
			32.7% for BRV 50 mg/day*
Kwan et al^Citation31	BRV 359 (323 partial; 36 generalized)	Flexible doses	16.7% for PBO
		20–150 mg/day	30.3% in BRV group with partial seizures*
	PBO 121 (108 focal; 13 generalized)		15.4% for PBO
			44.4% in BRV group with generalized seizures
Klein et al^Citation32	BRV 501	100–200 mg/day	21.6% for PBO
	PBO 259 (partial)		38.9% for BRV 100 mg/day*
			37.8% for BRV 200 mg/day*

Notes:

* Significantly different (P<0.05) from placebo. Copyright ©2015. Dove Medical Press. Adapted from Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015;9:5719–5725.¹¹

Abbreviations: BRV, brivaracetam; ITT, intention-to-treat; NR, not reported data; PBO, placebo.

Table 2 Most common adverse effects of BRV in six randomized, placebo-controlled clinical trials

Trial	Headache	Somnolence	Fatigue	Dizziness	Gastrointestinal disturbance
French et al^Citation27	BRV 5: 8%	BRV 5: 2%	BRV 5: 0%	BRV 5: 2%	NR
	BRV 20: 3.8%	BRV 20: 5.8%	BRV 20: 3.8%	BRV 20: 0%
	BRV 50: 1.9%	BRV 50: 5.8%	BRV 50: 5.8%	BRV 50: 7.7%
	PBO: 7.4%	PBO: 7.4%	PBO: 3.7%	PBO: 5.6%
Van Paesschen et al^Citation28	BRV 50: 15.1%	BRV 50: 9.4%	BRV 50: 13.2%	BRV 50: 3.8%	BRV 50: 9.4%
	BRV 150: 7.7%	BRV 150: 5.8%	BRV 150: 5.8%	BRV 150: 9.6%	BRV 150: 19.3%
	PBO: 7.7%	PBO: 5.8%	PBO: 7.7%	PBO: 5.8%	PBO: 15.3%
Ryvlin et al^Citation29	BRV 20: 14.1%	BRV 20: 8.1%	BRV 20: 3%	BRV 20: 5.1%	BRV 20: 0%
	BRV 50: 18.2%	BRV 50: 6.1%	BRV 50: 4%	BRV 50: 7.1%	BRV 50: 1%
	BRV 100: 9%	BRV 100: 8%	BRV 100: 8%	BRV 100: 5%	BRV 100: 6%
	PBO: 9%	PBO: 6%	PBO: 2%	PBO: 8%	PBO: 4%
Biton et al^Citation30	BRV 5: 11.3%	BRV 5: 14.4%	BRV 5: 3.1%	BRV 5: 12.4%	BRV 5: 11.3%
	BRV 20: 6%	BRV 20: 14%	BRV 20: 13%	BRV 20: 14%	BRV 20: 12%
	BRV 50: 13%	BRV 50: 16.8%	BRV 50: 9.9%	BRV 50: 15.8%	BRV 50: 16.8%
	PBO: 14.3%	PBO: 7.1%	PBO: 2%	PBO: 9.2%	PBO: 6.1%
Kwan et al^Citation31	BRV: 14.2%	BRV: 14.1%	BRV: 7.8%	BRV: 8.6%	BRV: 5.6%
	PBO: 19.8%	PBO: 4.1%	PBO: 4.1%	PBO: 5.8%	PBO: 8.3%
Klein et al^Citation32	BRV 100: 6.7%	BRV 100: 19.4%	BRV 100: 7.5%	BRV 100: 10.3%	NR
	BRV 200: 8.0%	BRV 200: 16.8%	BRV 200: 11.6%	BRV 200: 14.4%
	PBO: 8.4%	PBO: 7.7%	PBO: 3.8%	PBO: 5%

Notes: Data from these studies.^27–32 Dose for BRV is mg/day.

Abbreviations: BRV, brivaracetam; NR, not reported; PBO, placebo.

FrenchJACostantiniCBrodskyAvon RosenstielPGroupNSAdjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trialNeurology201075651952520592253

 PubMed Web of Science ®Google Scholar

Van PaesschenWHirschEJohnsonMFalterUvon RosenstielPEfficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trialEpilepsia2013541899722813235

 PubMed Web of Science ®Google Scholar

RyvlinPWerhahnKJBlaszczykBJohnsonMELuSAdjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trialEpilepsia2014551475624256083

 PubMed Web of Science ®Google Scholar

BitonVBerkovicSFAbou-KhalilBSperlingMRJohnsonMELuSBrivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trialEpilepsia2014551576624446953

 PubMed Web of Science ®Google Scholar

KwanPTrinkaEVan PaesschenWRektorIJohnsonMELuSAdjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trialEpilepsia2014551384624116853

 PubMed Web of Science ®Google Scholar

KleinPSchiemannJSperlingMRA randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizuresEpilepsia Epub20151016

 Web of Science ®Google Scholar

MumoliLPalleriaCGaspariniSBrivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizuresDrug Des Devel Ther2015957195725

 PubMed Web of Science ®Google Scholar